The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study
Open accessAbstract
Background: Inotuzumab ozogamicin (InO) is an antibody‐drug conjugate used for adults with relapsed/refractory B‐cell precursor (BCP) acute lymphoblastic leukemia (ALL). The INotuzumab Ozogamicin trial to inVestigAte Tolerability and Efficacy (INO‐VATE) previously reported improved outcomes with InO versus standard‐of‐care (SoC) chemotherapy. This article reports the final INO‐VATE results (≥2 years of follow‐up) and additional analyses of patient characteristics associated with improved outcomes. Methods: Between August 27, 2012, and January 4, 2015, this multicenter, parallel, open‐label, phase 3 trial randomized 326 adults with relapsed/refractory ALL to InO (n = 164) or SoC (n = 162); 307 received 1 or more doses of the study drug (164 in the InO arm and 143 in the SoC arm). Results: The complete remission (CR)/complete remission with incomplete hematologic recovery (CRi) rate was higher with InO versus SoC (73.8% vs 30.9%; 1‐sided P < .0001), with consistent CR/CRi rates across patient subgroups. The median overall survival (OS) was 7.7 months with InO and 6.2 months with SoC, with 2‐year OS rates of 22.8% and 10.0%, respectively (overall hazard ratio, 0.75; 97.5% confidence interval [CI], 0.57‐0.99; 1‐sided P = .0105). The predictors of OS with InO were the best minimal residual disease status, baseline platelet count, duration of first remission, achievement of CR/CRi, and follow‐up hematopoietic stem cell transplantation (HSCT; all 2‐sided P values < .05). More InO arm patients proceeded directly to HSCT after achieving CR/CRi before any follow‐up induction therapy (39.6% [95% CI, 32.1%‐47.6%] vs 10.5% [6.2%‐16.3%]; 1‐sided P < .0001). The most frequent all‐grade and grade 3 or higher adverse events in both arms were hematologic. Veno‐occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) was more frequent with InO (23 of 164 [14.0%] vs 3 of 143 [2.1%]). Conclusions: In patients with relapsed/refractory BCP ALL in INO‐VATE, InO was associated with a greater likelihood of CR/CRi across key patient subgroups, and it served as a bridge to HSCT. Potential VOD/SOS risk factors must be considered when InO treatment decisions are being made.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
Self-citationInotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O’Brien, S., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,413
Self-citationFielding, A. K., Richards, S. M., Chopra, R., Lazarus, H. M., Litzow, M. R., Buck, G., Durrant, I. J., Luger, S. M., Marks, D. I., Franklin, I. M., et al. (2007) · Blood · doi:10.1182/blood-2006-05-018192 · Cited by 841
Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
Uno, H., Claggett, B., Tian, L., Inoue, E., Gallo, P., Miyata, T., Schrag, D., Takeuchi, M., Uyama, Y., Zhao, L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2208 · Cited by 810
Royston, P., & Parmar, M. K. B. (2011) · Statistics in Medicine · doi:10.1002/sim.4274 · Cited by 585
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Haso, W., Lee, D. W., Shah, N. N., Stetler-Stevenson, M., Yuan, C. M., Pastan, I. H., Dimitrov, D. S., Morgan, R. A., FitzGerald, D. J., Barrett, D. M., et al. (2013) · Blood · doi:10.1182/blood-2012-06-438002 · Cited by 572
Gökbuget, N., Stanze, D., Beck, J., Diedrich, H., Horst, H.-A., Hüttmann, A., Kobbe, G., Kreuzer, K.-A., Leimer, L., Reichle, A., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399287 · Cited by 472
Self-citationDiJoseph, J. F., Armellino, D. C., Boghaert, E. R., Khandke, K., Dougher, M. M., Sridharan, L., Kunz, A., Hamann, P. R., Gorovits, B., Udata, C., et al. (2004) · Blood · doi:10.1182/blood-2003-07-2466 · Cited by 361
Tavernier, E., Boiron, J.-M., Huguet, F., Bradstock, K., Vey, N., Kovacsovics, T., Delannoy, A., Fegueux, N., Fenaux, P., Stamatoullas, A., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404824 · Cited by 256
Trinquart, L., Jacot, J., Conner, S. C., & Porcher, R. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2488 · Cited by 251
Kantarjian, H. M., Ravandi, F., Short, N. J., Huang, X., Jain, N., Sasaki, K., Daver, N. G., Pemmaraju, N., Khoury, J. D., Jorgensen, J. L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30011-1 · Cited by 239
Self-citationUno, H., Wittes, J., Fu, H., Solomon, S. D., Claggett, B., Tian, L., Cai, T., Pfeffer, M. A., Evans, S. R., & Wei, L.-J. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1741 · Cited by 220
Kantarjian, H. M., DeAngelo, D. J., Advani, A. S., Stelljes, M., Kebriaei, P., Cassaday, R. D., Merchant, A. A., Fujishima, N., Uchida, T., Calbacho, M., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30103-5 · Cited by 217
Self-citationOutcome of adults with acute lymphocytic leukemia after second salvage therapy
O'Brien, S. M., Thomas, D. M., Ravandi, F., Faderl, S. H., Cortes, J. E., Borthakur, G., Pierce, S. A., Garcia‐Manero, G., & Kantarjian, H. M. (2008) · Cancer · doi:10.1002/cncr.23919 · Cited by 150
Self-citationPreclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
Shor, B., Gerber, H., & Sapra, P. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.09.014 · Cited by 149
DeAngelo, D. J., Stock, W., Stein, A. S., Shustov, A. R., Liedtke, M., Schiffer, C. A., Vandendries, E. R., Liau, K., Ananthakrishnan, R., Boni, J. P., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016001925 · Cited by 137
Self-citationOliansky, D. M., Camitta, B. M., Gaynon, P. S., Nieder, M. L., Parsons, S. K., Pulsipher, M. A., Dillon, H., Ratko, T. A., Wall, D. A., McCarthy, P. L., et al. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.12.585 · Cited by 120
Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia
Jabbour, E. J., Pui, C., & Kantarjian, H. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1915 · Cited by 103
Self-citationYurkiewicz, I. R., Muffly, L. S., & Liedtke, M. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s150317 · Cited by 63
Self-citationMcDonald, G. B., Freston, J. W., Boyer, J. L., & DeLeve, L. D. (2018) · Hepatology · doi:10.1002/hep.30222 · Cited by 55
Cited by
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Antibody–drug conjugates come of age in oncology
Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M., & Beck, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00709-2 · Cited by 842
Shah, B. D., Ghobadi, A., Oluwole, O. O., Logan, A. C., Boissel, N., Cassaday, R. D., Leguay, T., Bishop, M. R., Topp, M. S., Tzachanis, D., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01222-8 · Cited by 820
Self-citationAntibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Malard, F., & Mohty, M. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33018-1 · Cited by 773
Metadata
- Authors
- Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gökbuget, N., O’Brien, S. M., Jabbour, E., Wang, T., Liang White, J., Sleight, B., Vandendries, E., & Advani, A. S.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2019-03-28
- Volume
- 125
- Issue
- 14
- Pages
- 2474-2487
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2931981435
- Cited by
- 343
- References
- 21
- FWCI
- 33.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.